查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594477

神经病变疼痛治疗​​市场：按疼痛类型、适应症、治疗方法、分销管道和最终用户划分 - 2025-2030 年全球预测

Neuropathy Pain Treatment Market by Pain Type, Indication, Treatment, Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年神经病变疼痛治疗​​市值为77.4亿美元，预计2024年将达到85.9亿美元，复合年增长率为11.53%，2030年将达到166.1亿美元。

神经病变疼痛治疗​​包括旨在减轻与神经病变疼痛相关的不适的治疗方法和药物，神经性疼痛通常是由多种原因引起的神经损伤引起的，包括糖尿病、化疗和身体损伤。神经病变疼痛的慢性和使人衰弱的性质强调了这种治疗的必要性，它对生活品质有重大影响，需要有效的管理策略。神经病变疼痛的治疗范围从药物、医疗设备到针灸和生活方式改变等替代疗法。最终用途主要包括医院和门诊诊所等医疗机构，以及为寻求便利的慢性疾病患者提供的居家照护环境。

主要市场统计
基准年[2023] 77.4亿美元
预测年份 [2024] 85.9亿美元
预测年份 [2030] 166.1亿美元
复合年增长率（%） 11.53%

糖尿病和癌症盛行率的增加、老年人口的增加以及对神经病变疾病和可用治疗方法的认识不断增强，极大地推动了市场成长。药物输送系统的技术进步和新型疼痛管理设备的开发将进一步支持市场扩张。此外，个人化医疗和人工智慧的整合可以实现更好的诊断和个人化治疗，有机会显着改善患者的治疗效果。然而，市场开拓受到药物开发成本高、监管核准严格以及长期使用神经病变药物相关副作用风险等挑战的阻碍。

该领域的创新应集中于开发非成瘾性和更有效的镇痛药物以及寻找神经保护剂以预防神经病变疾病的发作和进展。对神经病理性疼痛的遗传基础的研究也可能导致标靶治疗的突破。在持续的技术创新和研发投入的推动下，市场竞争激烈。鼓励公司优先考虑与研究机构建立伙伴关係和合作，以推进药物发现，并参与以患者为中心的产品开发，以有效满足不断变化的需求。

市场动态：揭示快速发展的神经病变疼痛治疗​​市场的关键市场洞察

供需的动态交互作用正在改变神经病变疼痛治疗​​市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 神经病变疼痛患者数量不断增加
    • 全球医疗保健支出增加
    • 神经病变疼痛缓解剂和非处方产品的增加
  • 市场限制因素
    • 对可用治疗方案缺乏认识
  • 市场机会
    • 介绍新的疼痛治疗方法
    • 专注于安宁疗护的计划和倡议
  • 市场挑战
    • 确定患者神经病变疼痛的适当治疗方法的复杂性

波特的五力：驾驭神经病变疼痛治疗​​市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解神经病变疼痛治疗​​市场的外部影响

外部宏观环境因素在塑造神经病变疼痛治疗​​市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解神经病变疼痛治疗​​市场的竞争格局

对神经病变疼痛治疗​​市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵神经病变疼痛治疗​​市场供应商的绩效评估

FPNV 定位矩阵是评估神经病变疼痛治疗​​市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了神经病变疼痛治疗​​市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对神经病变疼痛治疗​​市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人群中神经病变疼痛的增加
      • 全球医疗保健成本上升
      • 神经病变疼痛缓解药物和非处方药的增加
    • 抑制因素
      • 对可用治疗方案的认识有限
    • 机会
      • 介绍新的疼痛治疗替代方案
      • 专注于安宁疗护的计划和倡议
    • 任务
      • 确定患者神经病变疼痛的适当治疗方法的复杂性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依疼痛类型分類的神经病变疼痛治疗​​市场

  • 尾骨疼痛
  • 绞窄性神经病变
  • 脚痛
  • 週边神经神经病变
  • 幻肢神经病变
  • 带状疱疹后遗症神经痛(PHN)
  • 神经病变
  • 三叉神经痛

第七章神经病变疼痛治疗​​市场（按适应症）

  • 化疗引起的周边神经病变
  • 糖尿病神经病变
  • 脊椎狭窄

第八章神经病变疼痛治疗​​市场（依治疗）

  • 药品
    • 抗忧郁症的类型
      • 血清素去甲肾上腺素
      • 三环抗忧郁药物
    • 药品类型
    • 多模态治疗
    • 非类固醇抗发炎药类型
      • Ibuprofen
      • 萘普生
  • 治疗

第九章神经病变疼痛治疗​​市场：按分销管道

  • 网路药房
  • 零售药局/药局

第 10 章神经病变疼痛治疗​​市场：依最终使用者分类

  • 诊所
  • 医院

第十一章美洲神经病变疼痛治疗​​市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区神经病变疼痛治疗​​市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的神经病变疼痛治疗​​市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Assertio Holdings, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson and Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
Product Code: MRR-957C47F9180B

The Neuropathy Pain Treatment Market was valued at USD 7.74 billion in 2023, expected to reach USD 8.59 billion in 2024, and is projected to grow at a CAGR of 11.53%, to USD 16.61 billion by 2030.

Neuropathy pain treatment encompasses therapies and medications aimed at alleviating the discomfort associated with neuropathic pain, a condition often resulting from nerve damage due to various causes like diabetes, chemotherapy, or physical injury. The necessity of such treatments is underscored by the chronic and debilitating nature of neuropathic pain, which can significantly impact quality of life and necessitates effective management strategies. The application scope of neuropathy pain treatment spans across pharmaceuticals, medical devices, and alternative therapies such as acupuncture and lifestyle modifications. End-use predominantly involves healthcare facilities like hospitals and outpatient clinics, alongside home care settings for chronic sufferers seeking convenience.

KEY MARKET STATISTICS
Base Year [2023] USD 7.74 billion
Estimated Year [2024] USD 8.59 billion
Forecast Year [2030] USD 16.61 billion
CAGR (%) 11.53%

The market's growth is largely propelled by the increasing prevalence of diabetes and cancer, rising geriatric population, and the escalating awareness about neuropathic conditions and available treatments. Technological advancements in drug delivery systems and the development of novel pain management devices further fuel market expansion. Moreover, there are opportunities in personalized medicine and the integration of artificial intelligence for better diagnosis and treatment personalization, which can significantly elevate patient outcomes. Nonetheless, market growth is challenged by factors like high drug development costs, stringent regulatory approvals, and the risk of side effects associated with long-term usage of neuropathic medications.

Innovation in this sector should focus on developing non-addictive and more effective analgesics, as well as exploring neuroprotective agents that can prevent the onset or progression of neuropathic damage. Researching the genetic basis of neuropathic pain could also lead to breakthroughs in targeted therapy. The nature of the neuropathy pain treatment market is highly competitive, driven by continuous innovation and R&D investments. Companies are recommended to prioritize partnerships and collaborations with research institutions to advance drug discovery and to engage in patient-centric product development to meet evolving demands efficiently.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neuropathy Pain Treatment Market

The Neuropathy Pain Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in neuropathic pain among population
    • Increasing global healthcare expenditure
    • Growing number of neuropathic pain relievers and over-the-counter products
  • Market Restraints
    • Limited awareness of available treatment options
  • Market Opportunities
    • Introduction of novel pain treatment alternatives
    • Programs and initiatives focusing on palliative care
  • Market Challenges
    • Complexity in identifying the treatment suitable for neuropathic pains in a patient

Porter's Five Forces: A Strategic Tool for Navigating the Neuropathy Pain Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neuropathy Pain Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neuropathy Pain Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neuropathy Pain Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neuropathy Pain Treatment Market

A detailed market share analysis in the Neuropathy Pain Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neuropathy Pain Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neuropathy Pain Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neuropathy Pain Treatment Market

A strategic analysis of the Neuropathy Pain Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuropathy Pain Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Assertio Holdings, Inc., Astellas Pharma Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Biogen Inc., Bristol Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, GlaxoSmithKline PLC, Johnson and Johnson Services, Inc., Novartis AG, Pfizer Inc., and Sun Pharmaceutical Industries Limited.

Market Segmentation & Coverage

This research report categorizes the Neuropathy Pain Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Pain Type, market is studied across Coccydynia, Entrapment Neuropathy, Foot Pain, Peripheral Neuropathy, Phantom Limb Neuropathy, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, and Trigeminal Neuralgia.
  • Based on Indication, market is studied across Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy, and Spinal Stenosis.
  • Based on Treatment, market is studied across Drugs and Therapy. The Drugs is further studied across Antidepressant Drugs Type, Medication Type, Multimodal Therapy, and NSAIDs Type. The Antidepressant Drugs Type is further studied across Serotonin Noradrenaline and Tricyclic Antidepressants. The NSAIDs Type is further studied across Ibuprofen and Naproxen.
  • Based on Distribution Channel, market is studied across Online Pharmacies and Retail Pharmacies & Drug Stores.
  • Based on End-User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in neuropathic pain among population
      • 5.1.1.2. Increasing global healthcare expenditure
      • 5.1.1.3. Growing number of neuropathic pain relievers and over-the-counter products
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness of available treatment options
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel pain treatment alternatives
      • 5.1.3.2. Programs and initiatives focusing on palliative care
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in identifying the treatment suitable for neuropathic pains in a patient
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neuropathy Pain Treatment Market, by Pain Type

  • 6.1. Introduction
  • 6.2. Coccydynia
  • 6.3. Entrapment Neuropathy
  • 6.4. Foot Pain
  • 6.5. Peripheral Neuropathy
  • 6.6. Phantom Limb Neuropathy
  • 6.7. Post Herpetic Neuralgia (PHN)
  • 6.8. Post Traumatic Neuropathy
  • 6.9. Trigeminal Neuralgia

7. Neuropathy Pain Treatment Market, by Indication

  • 7.1. Introduction
  • 7.2. Chemotherapy-Induced Peripheral Neuropathy
  • 7.3. Diabetic Neuropathy
  • 7.4. Spinal Stenosis

8. Neuropathy Pain Treatment Market, by Treatment

  • 8.1. Introduction
  • 8.2. Drugs
    • 8.2.1. Antidepressant Drugs Type
      • 8.2.1.1. Serotonin Noradrenaline
      • 8.2.1.2. Tricyclic Antidepressants
    • 8.2.2. Medication Type
    • 8.2.3. Multimodal Therapy
    • 8.2.4. NSAIDs Type
      • 8.2.4.1. Ibuprofen
      • 8.2.4.2. Naproxen
  • 8.3. Therapy

9. Neuropathy Pain Treatment Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies & Drug Stores

10. Neuropathy Pain Treatment Market, by End-User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Hospitals

11. Americas Neuropathy Pain Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Neuropathy Pain Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Neuropathy Pain Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Assertio Holdings, Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Aurobindo Pharma Limited
  • 6. Baxter International Inc.
  • 7. Biogen Inc.
  • 8. Bristol Myers Squibb Company
  • 9. Dr. Reddy's Laboratories Ltd.
  • 10. Eli Lilly and Company
  • 11. GlaxoSmithKline PLC
  • 12. Johnson and Johnson Services, Inc.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. NEUROPATHY PAIN TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. NEUROPATHY PAIN TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. NEUROPATHY PAIN TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. NEUROPATHY PAIN TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEUROPATHY PAIN TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEUROPATHY PAIN TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COCCYDYNIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ENTRAPMENT NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY FOOT PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PERIPHERAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PHANTOM LIMB NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY POST HERPETIC NEURALGIA (PHN), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY POST TRAUMATIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SPINAL STENOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SEROTONIN NORADRENALINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MEDICATION TYPE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MULTIMODAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 20